Literature DB >> 20677926

Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells.

Elisa Galende1, Ioannis Karakikes, Lisa Edelmann, Robert J Desnick, Thomas Kerenyi, Georges Khoueiry, James Lafferty, Joseph T McGinn, Michael Brodman, Valentin Fuster, Roger J Hajjar, Katalin Polgar.   

Abstract

Recently, cultured human adult skin cells were reprogrammed to induced pluripotent stem (iPS) cells, which have characteristics similar to human embryonic stem (hES) cells. Patient-derived iPS cells offer genetic and immunologic advantages for cell and tissue replacement or engineering. The efficiency of generating human iPS cells has been very low; therefore an easily and efficiently reprogrammed cell type is highly desired. Here, we demonstrate that terminally differentiated human amniotic fluid (AF) skin cells provide an accessible source for efficiently generating abundant-induced pluripotent stem (AF-iPS) cells. By induction of pluripotency with the transcription factor quartet (OCT3/4, SOX2, KLF4, and c-MYC) the terminally differentiated, cultured AF skin cells formed iPS colonies approximately twice as fast and yielded nearly a two-hundred percent increase in number, compared to cultured adult skin cells. AF-iPS cells were identical to hES cells for morphological and growth characteristics, antigenic stem cell markers, stem cell gene expression, telomerase activity, in vitro and in vivo differentiation into the three germ layers and for their capacity to form embryoid bodies (EBs) and teratomas. Our findings provide a biological interesting conclusion that these fetal AF cells are more rapidly, easily, and efficiently reprogrammed to pluripotency than neonatal and adult cells. AF-iPS cells may have a "young," more embryonic like epigenetic background, which may facilitate and accelerate pluripotency. The ability to efficiently and rapidly reprogram terminally differentiated AF skin cells and generate induced pluripotent stem cells provides an abundant iPS cell source for various basic studies and a potential for future patient-specific personalized therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20677926      PMCID: PMC2998987          DOI: 10.1089/cell.2009.0077

Source DB:  PubMed          Journal:  Cell Reprogram        ISSN: 2152-4971            Impact factor:   1.987


  35 in total

1.  Characterization of rapidly adhering amniotic fluid cells by combined immunofluorescence and phagocytosis assays.

Authors:  K Polgár; R Adány; G Abel; J Kappelmayer; L Muszbek; Z Papp
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

Review 2.  Amniotic fluid and placental stem cells.

Authors:  Dario Fauza
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2004-12       Impact factor: 5.237

3.  ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities.

Authors: 
Journal:  Obstet Gynecol       Date:  2007-01       Impact factor: 7.661

4.  Isolation of amniotic stem cell lines with potential for therapy.

Authors:  Paolo De Coppi; Georg Bartsch; M Minhaj Siddiqui; Tao Xu; Cesar C Santos; Laura Perin; Gustavo Mostoslavsky; Angéline C Serre; Evan Y Snyder; James J Yoo; Mark E Furth; Shay Soker; Anthony Atala
Journal:  Nat Biotechnol       Date:  2007-01-07       Impact factor: 54.908

5.  A fresh look at iPS cells.

Authors:  Shinya Yamanaka
Journal:  Cell       Date:  2009-04-03       Impact factor: 41.582

6.  Induced pluripotent stem cells from a spinal muscular atrophy patient.

Authors:  Allison D Ebert; Junying Yu; Ferrill F Rose; Virginia B Mattis; Christian L Lorson; James A Thomson; Clive N Svendsen
Journal:  Nature       Date:  2008-12-21       Impact factor: 49.962

7.  Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases.

Authors:  Lin Ye; Judy C Chang; Chin Lin; Xiaofang Sun; Jingwei Yu; Yuet Wai Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-29       Impact factor: 11.205

Review 8.  Epidermal neural crest stem cells (EPI-NCSC) and pluripotency.

Authors:  Maya Sieber-Blum; Yaofei Hu
Journal:  Stem Cell Rev       Date:  2008-12       Impact factor: 5.739

9.  Virus-free induction of pluripotency and subsequent excision of reprogramming factors.

Authors:  Keisuke Kaji; Katherine Norrby; Agnieszka Paca; Maria Mileikovsky; Paria Mohseni; Knut Woltjen
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

10.  piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells.

Authors:  Knut Woltjen; Iacovos P Michael; Paria Mohseni; Ridham Desai; Maria Mileikovsky; Riikka Hämäläinen; Rebecca Cowling; Wei Wang; Pentao Liu; Marina Gertsenstein; Keisuke Kaji; Hoon-Ki Sung; Andras Nagy
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

View more
  37 in total

Review 1.  Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues.

Authors:  Hassan Abdulrazzak; Dafni Moschidou; Gemma Jones; Pascale V Guillot
Journal:  J R Soc Interface       Date:  2010-08-25       Impact factor: 4.118

2.  Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions.

Authors:  Jaroslav Slamecka; Lilia Salimova; Steven McClellan; Mathieu van Kelle; Debora Kehl; Javier Laurini; Paolo Cinelli; Laurie Owen; Simon P Hoerstrup; Benedikt Weber
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes.

Authors:  Ioannis Karakikes; Grant D Senyei; Jens Hansen; Chi-Wing Kong; Evren U Azeloglu; Francesca Stillitano; Deborah K Lieu; Jiaxian Wang; Lihuan Ren; Jean-Sebastien Hulot; Ravi Iyengar; Ronald A Li; Roger J Hajjar
Journal:  Stem Cells Transl Med       Date:  2013-12-09       Impact factor: 6.940

Review 4.  Advancements in reprogramming strategies for the generation of induced pluripotent stem cells.

Authors:  Mei I Lai; Wai Yeng Wendy-Yeo; Rajesh Ramasamy; Norshariza Nordin; Rozita Rosli; Abhi Veerakumarasivam; Syahril Abdullah
Journal:  J Assist Reprod Genet       Date:  2011-03-09       Impact factor: 3.412

Review 5.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

Review 6.  Osteogenic differentiation of amniotic fluid mesenchymal stromal cells and their bone regeneration potential.

Authors:  Caterina Pipino; Assunta Pandolfi
Journal:  World J Stem Cells       Date:  2015-05-26       Impact factor: 5.326

7.  Pushing the reset button: chemical-induced conversion of amniotic fluid stem cells into a pluripotent state.

Authors:  Sebastian Diecke; Joseph C Wu
Journal:  Mol Ther       Date:  2012-10       Impact factor: 11.454

8.  Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Delaine K Ceholski; Irene C Turnbull; Chi-Wing Kong; Simon Koplev; Joshua Mayourian; Przemek A Gorski; Francesca Stillitano; Angelos A Skodras; Mathieu Nonnenmacher; Ninette Cohen; Johan L M Björkegren; Daniel R Stroik; Razvan L Cornea; David D Thomas; Ronald A Li; Kevin D Costa; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2018-05-09       Impact factor: 5.000

9.  The LARGE principle of cellular reprogramming: lost, acquired and retained gene expression in foreskin and amniotic fluid-derived human iPS cells.

Authors:  Katharina Wolfrum; Ying Wang; Alessandro Prigione; Karl Sperling; Hans Lehrach; James Adjaye
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

10.  Human Cardiomyocytes Prior to Birth by Integration-Free Reprogramming of Amniotic Fluid Cells.

Authors:  Guihua Jiang; Todd J Herron; Julie Di Bernardo; Kendal A Walker; K Sue O'Shea; Shaun M Kunisaki
Journal:  Stem Cells Transl Med       Date:  2016-07-27       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.